← Product Code [OUP](/submissions/SU/subpart-e%E2%80%94surgical-devices/OUP) · K150505 # Cellfina System (K150505) _Ulthera, Inc. · OUP · Jul 29, 2015 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/OUP/K150505 ## Device Facts - **Applicant:** Ulthera, Inc. - **Product Code:** [OUP](/submissions/SU/subpart-e%E2%80%94surgical-devices/OUP.md) - **Decision Date:** Jul 29, 2015 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4790 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use The Cellfina™ System is intended for long term improvement in the appearance of cellulite in the buttocks and thigh areas of adult females as supported by clinical data demonstrating no significant reduction in treatment benefits up to 2 years of observation. ## Device Story Cellfina System is a minimally invasive surgical device used in clinics by physicians to treat cellulite. It utilizes a powered motor module to drive a mechanical cutting blade, which performs controlled, focal release of subcutaneous fibrous septae. The system includes a sterile, single-use disposable kit and a reusable motor module. The physician uses the device to stabilize and control the depth, size, and shape of the tissue release. By severing the fibrous bands that contribute to cellulite dimpling, the device provides a long-term aesthetic improvement. The procedure is performed under local anesthesia. Clinical outcomes are assessed via physician review of standardized photographs and patient satisfaction surveys. The device benefits patients by providing a durable reduction in cellulite severity. ## Clinical Evidence Prospective, multi-center, non-randomized, open-label study (IDE G120116) evaluated safety and efficacy in adult females (n=not specified) over 2 years. Primary endpoint: ≥1 point reduction in Cellulite Severity Scale (0-5) at 2 years via independent blinded photo review; mean improvement was 2.0 points (p<0.0001). Secondary endpoint: >60% of subjects showed ≥1 grade improvement; 88.5% achieved this. 100% of subjects were free from serious adverse events. 96% of subjects were satisfied/very satisfied at 2 years. ## Technological Characteristics Powered surgical instrument; mechanical cutting via wall-powered motor module. Disposable kit components include molded parts, PTFE tubes, and Loctite 4311 adhesive. Sterilization via Ethylene Oxide (SAL 10-6). Device is standalone; includes firmware-based fuse for safety. Biocompatible materials used for patient-contacting components. ## Regulatory Identification A powered surgical instrument for improvement in the appearance of cellulite is a prescription device that is used for the controlled release of subcutaneous tissue for improvement in the appearance of cellulite. The device consists of a cutting tool powered by a motor and a means for instrument guidance to control the areas of subcutaneous tissue cutting underneath the cellulite depressions or dimples. ## Special Controls In addition to the general controls of the FD&C Act, the Cabochon System is subject to the following special controls: *Classification.* Class II (special controls). The special controls for this device are:(1) Non-clinical testing must be performed to demonstrate that the device meets all design specifications and performance requirements, and to demonstrate durability and mechanical integrity of the device. (2) In vivo evaluation of the device must demonstrate device performance, including the safety of the release methodology and blood loss at the treatment sites. (3) All elements of the device that may contact the patient must be demonstrated to be biocompatible. (4) Electrical safety and electromagnetic compatibility of the device must be demonstrated. (5) The labeling must include a summary of in vivo evaluation data and all the device specific warnings, precautions, and/or contraindications. (6) Sterility and shelf-life testing for the device must demonstrate the sterility of patient contacting components and the shelf life of these components. ## Predicate Devices - Cellfina System ([K134010](/device/K134010.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized human figure with three faces in profile, representing health and well-being. The figure is enclosed within a circular border that contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA". Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Ulthera Incorporated Ms. Suzon Lommel Vice President Regulatory and Quality Affairs 1840 South Stapley Drive, Suite 200 Mesa, Arizona 85204 Re: K150505 Trade/Device Name: Cellfina™ System Regulation Number: 21 CFR 878.4790 Regulation Name: Powered surgical instrument for improvement in the appearance of cellulite Regulatory Class: Class II Product Code: OUP Dated: June 24, 2015 Received: June 30, 2015 Dear Ms. Lommel: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. July 29, 2015 If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical {1}------------------------------------------------ device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, Joshua C. Nipper -S Binita S. Ashar, M.D., M.B.A., F.A.C.S. For Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K150505 Device Name Cellfina™ System Indications for Use (Describe) The Cellfina™ System is intended for long term improvement in the appearance of cellulite in the buttocks and thigh areas of adult females as supported by clinical data demonstrating no significant reduction in treatment benefits up to 2 vears of observation. Type of Use (Select one or both, as applicable) > Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ # 5. 510(k) Summary This 510(k) Summary for the Cellfina™ System is submitted in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990 and follows the Office of Device Evaluation (ODE) guidance concerning the organization and content of a 510(k) summary. | Applicant: | Ulthera, Inc. | | |--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Address: | 1840 South Stapley Drive
Suite 200
Mesa, AZ 85204 | | | Contact Person: | Suzon Lommel, Vice President Regulatory and Quality Affairs | | | Telephone: | (408) 645-4979 | | | Fax: | (480) 619-4071 | | | Submission Date: | February 20, 2015 | | | Device Trade Name: | Cellfina System | | | Common Name: | Powered surgical instrument for improvement in the appearance of
cellulite. | | | Classification: | Regulatory Class II | | | Classification Name: | Powered surgical instrument for improvement in the appearance of
cellulite. | | | Regulation Number: | 21CFR 878.4790 | | | Product Code: | OUP | | | Legally Marketed Predicate: | Cellfina System (trade name previously Cabochon System), 510(k):
K134010 | | | Applicable Guidance: | The following guidance special controls are applicable to the Cellfina
System: | | | | Predicate Device
K134010, Cellfina System | Subject Device
Cellfina System | | Intended
Use/Indications for
Use | The Cellfina System is intended for long
term improvement in the appearance
of cellulite in the buttocks and thigh
areas of adult females as supported by
clinical data demonstrating no
significant reduction in treatment
benefits up to 1 year of observation. | The Cellfina System is intended for long
term improvement in the appearance
of cellulite in the buttocks and thigh
areas of adult females as supported by
clinical data demonstrating no
significant reduction in treatment
benefits up to 2 years of observation.

Clinical performance data provided for
expanded indication | | Where used | Clinic/Doctor's Office | Clinic/Doctor's Office | | | | Same | | Anatomical Site | Buttocks and thighs | Buttocks and thighs | | Type of Energy | Mechanical movement driven by wall powered motor module | Mechanical movement driven by wall powered motor module | | Biological Effect | Controlled mechanical cutting of the fibrous tissue (septae) which contributes to the appearance of cellulite.
The Cellfina System controls and stabilizes the cutting motion used by physicians with the needle based release procedure. | Controlled mechanical cutting of the fibrous tissue (septae) which contributes to the appearance of cellulite.
The Cellfina System controls and stabilizes the cutting motion used by physicians with the needle based release procedure. | | Location of Motor Module Label | Attached to the DC power cable | Adheres to the bottom of the motor module | | Sterilization | Disposable Kit, CK1:
Ethylene Oxide, SAL 10-6

Motor Module, CM1: Sterile dome provided; use with disinfecting wipes | No change to content
Disposable Kit, CK1:
Ethylene Oxide, SAL 10-6

Motor Module, CM1: Sterile dome provided; use with disinfecting wipes | | Shelf Life | Disposable Kit, CK1: 6 months

Motor Module, CM1: Undefined uses | Disposable Kit, CK1: 6 months

Motor Module, CM1: 15 uses | | Packaging | Disposable Kit, CK1:
• 3 Tyvek pouches | Cleaning and Disinfection Data provided
Disposable Kit, CK1:
• 1 Thermoformed tray with Tyvek sealed outer tray | | | | | | | Inner shipping chipboard box Outer corrugated shipper box Motor Module, CM1: Packaged with disposable kit | Foam insert within outer corrugated shipper box Outer corrugated shipper box Larger size to accommodate tray Motor Module, CM1: individually packaged
Packaging Testing Provided | | Biocompatibility | Biocompatible | Biocompatible
Biocompatibility Testing Provided | | Electromagnetic
Compatibility
Standards | Compatible | Compatible | | Medical Electrical
Equipment Safety
Standards | Compatible | Same
Compatible
Medical Electrical Equipment Safety
Testing Provided | | Motor Module
(CM1) Design
Modifications | Motor Controller; Mechanical fuse in secondary box (motor controller)

3 piece enclosure design

Machined | Motor Controller; Firmware fuse integrated into motor module

2 piece enclosure design

Machined

Functional Testing Provided | | Disposable Kit
(CK1) Design
Modifications | Machined

Internal adhesive, Loctite 3321

1 PTFE cover (tube) for both the anesthesia needle and the blade | Molded; minor dimensional changes to bottom plate to mate with CM1 due to transition from machined to molded.

Internal adhesive, Loctite 4311

2 individual PTFE covers (tubes); one for the anesthesia needle and 1 for blade

Functional Testing Provided | | Demonstrated
Safety and Efficacy
in treated area | Clinical performance data provided for safety and efficacy at 3 months under
IDE G120116 – De Novo K101231,
cleared July 12, 2013

Clinical performance data provided for safety and efficacy at 1 year under IDE
G120116 – 510(k) K134010, cleared
April 14, 2014 | Extended follow-up clinical
performance data provided for safety
and efficacy at 2 years under IDE
G120116

Clinical Follow-up Data Provided | Image /page/3/Picture/5 description: The image shows the logo for Ulthera, a company that specializes in medical aesthetic devices. The logo features the word "ulthera" in a sans-serif font, with the "u" and "l" in a light blue color and the rest of the letters in a darker shade of blue. To the right of the word, there are three orange circles arranged horizontally, followed by the trademark symbol. {4}------------------------------------------------ ### Class II (special controls). The special controls for this device are: - (1) Non-clinical testing must be performed to demonstrate that the device meets all design specifications and performance requirements, and to demonstrate durability and mechanical integrity of the device. - (2) In vivo evaluation of the device must demonstrate device performance, including the safety of the release methodology and blood loss at the treatment sites. - (3) All elements of the device that may contact the patient must be demonstrated to be biocompatible. - (4) Electrical safety and electromagnetic compatibility of the device must be demonstrated. - The labeling must include a summary of in vivo evaluation data and all the device specific (2) warnings, precautions, and/or contraindications. - (6) Sterility and shelf-life testing for the device must demonstrate the sterility of patient contacting components and the shelf life of these components. ### Device Description: The Cellfina System is intended to provide precise focal release of subcutaneous tissue for improvement in the appearance of cellulite. The release of subcutaneous tissue for improvement in the appearance of cellulite is a minimally invasive surgical technique by physicians using of manual surgical instruments and accessories. The Cellfina device consists of a powered cutting blade and a means for instrument guidance to control the depth, size and shape of the tissue release. The system consists of a sterile single use disposable kit and a non-sterile reusable motor module. #### Substantial Equivalence Comparison: Image /page/4/Picture/12 description: The image shows the logo for Ulthera, a company that specializes in medical aesthetic devices. The logo features the word "ulthera" in a sans-serif font, with the "u" and "l" in a light blue color and the rest of the letters in a darker shade of blue. Above the "era" portion of the word, there are three orange circles arranged horizontally. The TM symbol is located to the right of the word. {5}------------------------------------------------ Image /page/5/Picture/2 description: The image shows the word "ulthera" in a sans-serif font. The letters are a light blue color. To the right of the word are three yellow circles arranged horizontally. To the right of the circles is the trademark symbol. {6}------------------------------------------------ Image /page/6/Picture/2 description: The image shows the logo for Ulthera. The word "ulthera" is written in a sans-serif font, with the "u" and "l" in a light blue color and the rest of the letters in a darker blue. To the right of the word, there are three orange circles arranged horizontally, followed by the trademark symbol. {7}------------------------------------------------ # Bench Performance Data: Comprehensive bench testing has been successfully completed for the Cellfina System on aged product. Testing was performed on finished, sterile, aged devices that were exposed to environmental and transportation conditioning prior to testing which included simulated use, durability, and mechanical integrity. All devices were shown to meet the predetermined acceptance criteria. # Clinical Performance Data: The safety and effectiveness of the Cellfina System was evaluated in a pivotal clinical study conducted under IDE G120116. The IDE was modified to allow for extended follow-up clinical performance data to be gathered for safety and efficacy at 2 years. No additional treatments were performed. A prospective, multi-center, non-randomized open label, safety and effectiveness study was conducted for improvement of the appearance of cellulite. All subjects served as their own control and underwent a single treatment with the Cellfina System. Subjects underwent follow-up assessments at 3 days, 14 days, 1 year and 2 years post treatment. The subjects were asked to rate their satisfaction with their appearance and pain. Photographs were taken in accordance with a protocol-specific procedure at baseline and each follow-up. An independent and blinded reviewer of the photographs before treatment and at 2 years was used to verify the effectiveness of the procedure. A DSMB was formed and independently managed to provide safety oversight for the study. All endpoints were achieved. The primary safety endpoint, defined as freedom from serious adverse events attributable to the procedure or device was achieved for all subjects (100%). The overall study success criteria was met with a clinically significant, long term improvement in the appearance of cellulite in the treated subjects defined by the following: - The primary endpoint was met: achievement of ≥1 point average reduction in the 0-5 point Cellulite Severity Scale as determined by independent physician assessment of subject photographs taken before and 2 years after treatment. - o The average improvement was 2.0 points (p<0.0001) with the 97.5% confidence limit of a 1.8 point improvement. {8}------------------------------------------------ - The powered secondary endpoint was met: improvement of one grade or more in severity (none, mild, moderate, severe) in >60% of treated subjects as determined by independent physician assessment of subject photographs taken before and 2 years after treatment. - 88.5% of treated subjects had improvement of 1 grade with a 95% confidence limit of o 79.2%. - . The safety endpoint was met: 100% of subjects were free from Serious Adverse Events (SAE) directly attributable to the Cellfina™ System or procedure. All additional secondary measures were also achieved or acceptable at the 2 year timepoint: - The average rate of correct selection by independent physician assessment of blinded subject photographs taken before and was 98.1% with a 95% confidence limit of 94.5%. - . 100% of the subjects had noticeable improvement by the GAIS and 52% were characterized as having marked improvement or better by independent physician assessment of blinded subject photographs taken before and 2 years after treatment. - . 96% of the subjects were either satisfied or very satisfied as evaluated by a 5 point Likert type scale at the 2 year follow-up. - . Subject reported pain on a 0-10 numerical rating scale was 4.5 for the delivery of anesthesia and 3.7 for the tissue release portion of the procedure. For the follow-ups, 71% of subjects rated pain ≤ 3 at 3 days, and over 95% rated pain ≤ 3 thereafter. No subjects reported pain at the 2 year follow-up. # Conclusion Statements: This 510(k) Premarket Notification is for updated labeling of the Cellfina System based on completion of the 2 year follow-up from the pivotal trial. The clinical data demonstrates that the Cellfina System is both safe and effective for long term improvement in the appearance of cellulite. In addition, this 510(k) also includes modifications to the design of the Cellfina System for manufacturability and ease of customer use. Through comprehensive bench testing it has been confirmed that these changes do not pose any new questions of safety, product output or efficacy. As demonstrated through nonclinical and clinical tests, the Cellfina System is as safe, as effective, and performs as well as or better than the legally marketed predicate device (K134010) which was cleared on April 14, 2014, and as such, is substantially equivalent. Image /page/8/Picture/12 description: The image shows the logo for Ulthera. The word "ulthera" is written in lowercase letters, with the "u" and "l" in a light blue color and the rest of the letters in a darker blue. To the right of the word, there are three yellow circles arranged horizontally. The letters are stacked vertically, and the circles are to the right of the letters. --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/OUP/K150505](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/OUP/K150505) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com